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Abstract In bone disorders infections are common. The
concentration of majority of antibiotics is very low in the
bone tissue. A high local dose can be obtained from
the ciproﬂoxacin-loaded hydroxyapatite nanoparticles. The
present study is aimed at developing the use of hydroxy-
apatite and zinc-doped hydroxyapatite nanoparticles as a
carrier for ciproﬂoxacin drug delivery system. The cipro-
ﬂoxacin-loaded hydroxyapatite and zinc-doped hydroxy-
apatite have a good antibacterial activity against
Pseudomonas aeruginosa and Staphylococcus aureus.
Hydroxyapatite and zinc-doped hydroxyapatite were pre-
pared and characterized using X-ray diffraction, Trans-
mission electron microscopy and inductively coupled
plasma optical emission spectrometry. They were loaded
with ciproﬂoxacin using optimized drug loading parame-
ters. Drug loading, in vitro drug release and antimicrobial
activity were analyzed. The inﬂuence of zinc on the con-
trolled release of ciproﬂoxacin was analyzed. The results
show that the presence of zinc increases the drug release
percentage and that the drug was released in a controlled
manner.
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Introduction
Nanotechnology deals with the manipulation of material
characteristics (Ochekpe et al. 2009). Due to the large
surface to volume ratio they are advantageous to attach
drug molecules and other compounds (De Jong and Borm
2008). This is the main factor behind the application of
nanotechnology in medical ﬁeld for the delivery of drugs,
proteins or genes. The drugs are effectively delivered by
nanoparticles because nanoparticles are effectively taken
up by the cells. They penetrate deep into tissue through ﬁne
capillaries and cross the fenestration present in the epi-
thelial lining. Drug delivery can be either localized or
targeted to a particular diseased site (Panyam and Labha-
setwar 2003).
Controlled drug delivery is the technology by which the
drug can be released at a predetermined rate for a long
period of time into the blood or delivered at the target site
(Szycher 1986). Unlike the traditional oral, intravenous
drug delivery methods whereby the drug is distributed to
both healthy and diseased tissue, in controlled local drug
delivery high concentration of drug is achieved at the
infected site. This leads to increase in therapeutic index and
therapeutic efﬁcacy and reduction in overall serum con-
centration and deleterious side effects to other organs (De
Jong and Borm 2008; Melville et al. 2008; Noel MS et al.
2008; De Gaetano et al. 2005). Drug stability, optimized
drug absorption, treatment continuation in natural phase
and improvement in pharmacokinetic characteristics of
drug can be achieved by localized drug delivery (Somberg
1989). In controlled drug delivery system the carriers play
a vital role since they incorporate the drug, retain it
and release it progressively with time. So properties such
as drug incorporation and release; formulation stability
and shelf life; biocompatibility, biodistribution, and
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ing a carrier for delivery of drugs. The drug release from
any carrier depends upon solubility of drugs, microstruc-
ture of carrier, degradation of carrier and the bond between
the drug and the carrier (De Jong and Borm 2008; Ginebra
et al. 2006).
Bone diseases like osteomyelitis and osteoarticular
infections which are associated with bacterial infection are
highly complicated and involve operative debridement and
removal of all foreign bodies followed by antibiotic ther-
apy (Murugan and Ramakrishna 2006; Samit Kumar Nandi
et al. 2009; Gautier et al. 2001). The blood circulation in
these infected sites is limited and so the antibiotic distri-
bution is also poor. So growth factors and antimicrobials
should be supplied to the osseous site by site-speciﬁc drug
delivery (Hae-Won Kim et al. 2004). By this method the
drug action is localized and maintained for a long time. In
spite of high drug concentration at the infection site the
systemic side effects is low (Itokazu et al. 1999). By having
a localized drug delivery we can maintain a high concen-
tration of drug for a long time at the speciﬁc infected bone
site by controlling the release of drug. The drug concen-
tration can be controlled in a way that it neither reaches the
toxic level nor falls below the minimum effective level
(Ginebra et al. 2006). Even though high doses of antibiotics
are administered by systemic routes, effective drug con-
centration is not achieved at the site of infection because of
the impaired blood circulation, pharmacokinetic parame-
ters of the drug and high elimination rate (Pham et al. 2002;
Slosarczyk et al. 2000).
Staphylococcus aureus and Pseudomonas aeruginosa
are the most important pathogens causing bone and joint
infections, soft tissue and overwhelming sepsis. Staphylo-
coccus is a Gram-positive and Pseudomonas is a Gram-
negative bacterium. S. aureus expresses many surface
adhesions that promote attachment to plasma and extra
cellular matrix (ECM) proteins of the host cell. With the
use of new and high-dose antibacterial agents the fear of
new strain of S. aureus which is resistant to all available
antibacterial agents arises. S. aureus can evade the immune
response and antimicrobial therapy by another mechanism
known as ‘‘Small colony variants’’ (SCVs), a sub popula-
tion of S. aureus (Harris and Geoff Richards 2006; Uwe
Joosten et al. 2005).
Ciproﬂoxacin (CPX), 1-cyclopropyl 6-ﬂuro-1, 4-dihy-
dro-4-oxo-7-(1-piperazinyl)-3-quinoline carbolitic acid is a
broad-spectrum ﬂuroquinolone antibacterial agent used in
the treatment of both Gram-positive and Gram-negative
microorganisms. It stops cell division by inhibiting DNA
gyrase, a type II topoisomerase and topoisomerase IV. The
minimum inhibition concentration (MIC) of CPX is
0.25–2 lg/ml for pathogens like Staphylococcus aureus
and Pseudomonas aeruginosa which cause osteomyelitis.
With such a low MIC the dosage of CPX is 700 mg twice a
day for a period of 6 weeks to several months. The treat-
ment is extremely long and in spite of that the percentage
of cure is only 56%. This prolonged treatment and high
dose of CPX leads to toxicity and development of resistant
strains. So new sustained release systems have been pro-
posed as an alternative for systemic treatment (Patel et al.
2006; Zeiler 1985; Murugan and Panduranga Rao 2002).
Polymethymethacrylate (PMMA) beads have been used
initially to treat infectious bone diseases. But it has to be
removed surgically as they are non-biodegradable. Resorb-
able biomaterials like collagen, ﬁbrinogen and PLA when
useddo notreplace bonegrafting(Panyamand Labhasetwar
2003; Murugan and Ramakrishna 2006; Cheng and Kuhn
2007). Hydroxyapatite, a typical type of calcium phosphate
bioceramic, is used as a carrier for delivery of drugs, non
viral gene, antigen, enzyme and proteins because of their
biocompatibility, bioactivity and high afﬁnity towards
drugs, proteins and DNA. Since Hydroxyapatite has a low
solubility in physiological condition it can be used as a
carrier for the local delivery of drugs both by surgical
placement and injection. The controlled localized drug
deliveryfromhydroxyapatiteminimizesthetoxicitytoother
organs by minimizing the drug concentration in the blood. It
also avoids repeated dosage of drugs. Hydroxyapatite can
bind to both positive and negative molecules by simple
adsorption. So in the particulate form it is used for the
delivery of various kinds of molecules like antibiotics,
contraceptives, acetylsalicylic acid, hormones, insulin and
anticancer drugs (Paul and Sharma 1999; Madhana Sundar
et al. 2005; Szymura-Oleksiak et al. 2001). Hydroxyapatite
is used in the controlled drug delivery for bone cancer,
chronic osteomyelitis and in the delivery of agents with a
low bone penetration and short biological half life. The
concentration of drugdependsupon the ability ofthe drugto
penetrate through the micro pores of hydroxyapatite, rate of
penetration and the pharmacokinetic proﬁle of the drug.
Since hydroxyapatite has a micro pore structure and excel-
lent biological response to the physiological condition it can
ensure slow release of the drug (Slosarczyk et al. 2000;
Ingrid Russoni de Lima et al. 2006).
Zinc is an important trace element in all biological tis-
sues. More than 300 types of enzymes like alkaline phos-
phates take part in bone metabolism. Zinc participates in
the activity of these enzymes (Amit Bandyopadhyay et al.
2007). Zinc has a direct effect on the proliferative effect of
osteoblastic cells and inhibitory effect on osteoclastic bone
resorption (Tang et al. 2009). Besides these, zinc also takes
part in nucleic acid metabolism, maintenance of membrane
structure and its function, hormonal activity, biominerali-
zation and pathological calciﬁcation (Mason 2006). It acts
as an antioxidant. Many biochemical processes like car-
bohydrate metabolism, protein digestion and blood clotting
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123require zinc. It plays an important role in immune system
also. So it would be desirable to obtain hydroxyapatite with
certain amount of zinc to enhance several biochemical
processes (Say Chye Joachim Loo et al. 2008).
In the present work hydroxyapatite and zinc-doped
hydroxyapatite were synthesized in nano form and char-
acterized. Ciproﬂoxacin was loaded to both of these
materials. The various parameters for drug loading were
optimized. The drug loading percentage and drug release
proﬁle were analyzed and the inﬂuence of zinc on the
release of ciproﬂoxacin discussed. The interaction between
hydroxyapatite and drug was analyzed. Antimicrobial
activity of drug loaded hydroxyapatite was analyzed
against Pseudomonas aeruginosa and Staphylococcus
aureus.
Experimental procedure
Synthesis and characterization of hydroxyapatite
nanoparticles
Hydroxyapatite nanoparticles were synthesized by wet
chemical precipitation reaction:
10Ca OH ðÞ 2þ6H 3PO4 ! Ca10 PO4 ðÞ 6 OH ðÞ 2þ18H2O
Aqueous suspension o f calcium hydroxide (Ca (OH)2)
and orthophosphoric acid (H3PO4, 85%), both of analytical
grade, were used as reagents for the preparation. One liter
of an aqueous suspension of H3PO4 (0.6 M) was slowly
added drop by drop to one litre of an aqueous suspension of
Ca (OH)2 (1 M) while stirring for 2 h at room temperature
(Pataquiva Mateus et al. 2007). Concentrated NaOH was
added until a ﬁnal pH of 11 was obtained. The white
powder obtained was washed using deionized water and
dried in an oven at 80 C for 24 h (Edouard Jallot et al.
2005). Zinc-added hydroxyapatite was prepared by adding
Zn(NO3)2.6H2O to the solution. Four samples of
hydroxyapatite with zinc concentration of 2, 3, 4, 5 wt%
(Gibson et al. 1999) were obtained.
Powder X-ray Diffraction (XRD, Seifert, JSO-DE
BYEFLEX 2002, Germany) was utilized to identify the
crystalline phase composition. The morphology and crystal
structure of the product were observed by Transmission
Electron Microscopy (TEM). The instrument was JEOL
2000Fx-II operated at 200 kV, High Resolution, analytical
TEM with a W-source and a point–point resolution of 2 A ˚.
The functional groups present in the hydroxyapatite were
analyzed by FTIR (FTIR, Perkin Elmer Spectrum One).
Raman measurements were carried out using a Horiba
Jobin–Yvon-HR 800 UV micro-Raman setup. The 325-nm
line of He-Cd laser was used as the excitation source with a
2400 grooves mm
-1 grating in the backscattering
geometry. A 500-lm confocal pinhole was used to obtain
high-resolution Raman spectra. Energy Dispersive X-Ray
ﬂuorescence (EDX) is done with Hitachi VP-SEM
S-3400 N. Micro Hardness was analyzed using Leitz
Wetzlar Miniload 2 hardness tester equipped with a Mic-
roduromat 4000 E ﬁtted to the objective nosepiece (Reic-
hert-Jung Ltd). X-ray Photo electron spectroscopy (XPS)
was carried out by PHI 5000 Versa probe instrument. X-ray
Fluorescence Spectroscopy (XRF) was measured using
Rigaku ZSX Primus-II instrument.
Drug loading
In order to load drug on hydroxyapatite nanoparticles,
ciproﬂoxacin hydrochloride was dissolved in 100 ml of
distilled water at different concentrations (5, 10, 20%). 1 g
of hydroxyapatite nanoparticle was added to all the three
drug solutions and stirred using magnetic stirrer for various
time periods (20, 40, 80, 160 min) at various temperatures
(40, 50, 60, 70 C). Then the solution was left undisturbed
overnight. The suspension was then centrifuged (2249g,
5 min) and the supernatant and precipitate were separated.
The amount of drug loaded was determined by ﬁnding the
difference in ciproﬂoxacin concentration in the aqueous
solution before and after loading. Percentage of drug
loading is calculated using the following equation:
Percentage of drug loading ¼ A B ðÞ =A ½    100
where A and B represent the initial and ﬁnal drug con-
centration of the aqueous drug solution.
Drug loading on zinc-doped Hydroxyapatite was done in
the same way where instead of hydroxyapatite zinc-doped
hydroxyapatite was used. One gram of zinc-doped
hydroxyapatite (2, 3, 4, 5 wt%) was added to 5% cipro-
ﬂoxacin solution and stirred at optimized temperature and
for optimized time.
Pellets of 100 mg, 8 mm in diameter pressed with
100 MPa of pure hydroxyapatite, zinc-added hydroxyapa-
tite, ciproﬂoxacin-loaded hydroxyapatite and ciproﬂoxacin
(control) were made and used in antimicrobial studies.
Drug release-in vitro study
In order to determine the drug release proﬁle, 100 mg of
the drug-loaded hydroxyapatite and zinc-doped hydroxy-
apatite was introduced into a screw-capped glass bottle
containing 50 ml of phosphate-buffered saline (PBS)
medium at 37 C and pH 7.4 under sterile condition.
In vitro drug release study was done in static mode. The
drug release study was done for a period of 600 h. 5 ml
samples were withdrawn by a pipette and centrifuged at
2249g and replaced immediately with 5 ml of fresh PBS
medium, which was accounted for when calculating the
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123amount released. Ciproﬂoxacin concentration in the
supernatant was measured spectrophotometrically at a
wavelength of 274 nm. Drug release from zinc-doped
hydroxyapatite samples was also done in the same way.
Antibacterial activity
The antibacterial activity of pure hydroxyapatite, zinc-
doped hydroxyapatite nanoparticles and ciproﬂoxacin-loa-
ded hydroxyapatite and zinc-doped hydroxyapatite nano-
particles was tested by a quantitative diffusion disk test
using Staphylococcus aureus and Pseudomonas aerugin-
osa. They were cultured on Luria–Bertani (LB) agar plates.
Pellets of 100 mg, 8 mm in diameter pressed with 100 MPa
of pure hydroxyapatite, zinc-doped hydroxyapatite, cipro-
ﬂoxacin (control), ciproﬂoxacin-loaded hydroxyapatite and
ciproﬂoxacin-loaded hydroxyapatite zinc-doped hydroxy-
apatite nanoparticles were aseptically placed at the center of
the Petri plate. The plates were incubated for 24 h at 37 C.
The microbial inhibition zone was observed under optical
microscope. The inhibition zone of the samples and control
for the two different bacterial cultures were measured.
Results and discussions
Figure 1 shows the XRD pattern of pure hydroxyapatite
and zinc-doped hydroxyapatite nanoparticles. It shows the
formation of single-phase hydroxyapatite and the spectrum
matches with the JCPDS values (09-0432). The major
peaks indicate the crystalline form. The ‘a’ and ‘c’ value of
hydroxyapatite nanoparticles are 9.416 and 6.886 A ˚,
respectively, which are close to the lattice parameter of
stoichiometric hydroxyapatite (Powder diffraction ﬁle
ICDD 09-0432 a = 9.418 A ˚ and c = 6.884 A ˚). The inter-
planar distance d values agree well with the values esti-
mated from TEM. Table 1 depicts these values. The crys-
talline size of hydroxyapatite nanoparticles can be
calculated by Scherrer formula as follows:
Xhkl ¼ Kk=b1= 2Cos h
where Xhkl is the crystallite size (nm), k is the wavelength
of monochromatic X-ray beam (nm) (k = 0.15418 nm for
CuKa radiation), b  is the full width at half maximum for
the diffraction peak under consideration (rad), ‘h’ is the
diffraction angle (), and ‘K’ is a constant varying with
crystal habit and chosen to be 0.9. In the XRD pattern, the
(211) peak has the most distinct reﬂection. So, the mean
crystalline size is calculated with the line broadening of the
(211) reﬂection. The crystalline size of the pure hydroxy-
apatite crystals is about 52.00 nm.
In zinc-doped hydroxyapatite the zinc concentration
[Zn/(Ca ? Zn)] is expressed as the weight percentage of
zinc. The peak in the XRD pattern of zinc-doped
hydroxyapatite is identical to the XRD pattern of pure
hydroxyapatite and no other crystalline phase is detected.
As zinc concentration increases, the XRD peak of the
samples become broader, indicating lower crystallinity due
to the addition of zinc. Crystallinity, Xc is deﬁned as the
fraction of the cryslline phase in a sample volume. An
empirical relation between Xc and b1/2 is commonly
deduced according to the following equation:
Xc ¼ KA=b1=2
 3
where KA is a constant set at 0.24 and b1/2 is the FWHM of
the (211) reﬂection (in degrees). (Table 2) shows the single
crystal size and crystallinity of pure hydroxyapatite and
Zinc doped hydroxyapatite. As the zinc content increased,
both the crystallinity and crystal size decreased gradually.
Similar observation has been made by Bonﬁeld and his
group for silicon substitution (de Araujo et al. 2007). The
ionic radius is smaller for Zn
2? (0.074 nm) than that of
Ca
2? (0.099 nm), which might have distorted the crystal
structure of hydroxyapatite. The most important structure
parameters are the lattice parameters and unit cell volume,
which are shown in Table 3. The lattice parameter ‘a’
decreases with increasing Zn percentage. The lattice
parameter ‘c’ also decreases with increasing Zn fraction.
Such contraction in ‘a’ and ‘c’ due to the smaller ionic
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Fig. 1 XRD image of pure hydroxyapatite and zinc-doped
hydroxyapatite
Table 1 The comparison of values of d as calculated from the
electron diffraction pattern and calculation from the XRD pattern
Plane (peak
indexed as
in XRD)
XRD d value
Wave length
k = 1.542 A ˚
TEM d-value
(ﬁrst 3 rings)
Camera
constant = 0.0251 A ˚
002 3.48 3.44
211 2.79 2.77
212 2.25 2.24
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123radius of Zn
2? (0.074 nm) compared with that of Ca
2?
(0.099 nm) is reﬂected in the smaller unit cell volume with
Zn
2? addition.
The TEM image of pure hydroxyapatite nanoparticle is
presented in Fig. 2a. The picture conﬁrms the formation of
nanocrystalline powder. The particles are uniform and their
sizes range from 10 to 20 nm due to agglomeration. They
show needle-like structure. Fine discrete particles of nano
range are clearly visible in the loosely agglomerated
powder. The hydroxyapatite nanoparticles are crystalline as
can be seen from XRD. The nanocrystals exhibit sharp
edges and corners. The rate of nucleus formation and the
rate of growth are related to the concentration of reactants,
super saturation, temperature, stirring rate etc. TEM
micrographs of different zinc concentration are shown in
Fig. 2bi, ii, iii, iv. TEM micrographs show the inﬂuence of
zinc addition. On zinc incorporation the morphology of
hydroxyapatite changes. As the concentration of zinc
increases, agglomeration of particles also increases. The
zinc addition in hydroxyapatite structure causes a decrease
in the hydroxyapatite crystalline nature which may be due
to both substitutional and interstitial site occupancy of zinc
as discussed in the interpretation of Raman spectra and
XRD. There are no additional selected area diffraction
rings with addition of zinc up to 5 wt%. This conﬁrms the
structure as seen in XRD. The d-values as calculated from
the TEM electron diffraction rings exactly match with the
prominent peaks obtained from the XRD analysis (Fig. 1).
EDX analysis of Zinc-doped hydroxyapatite is given in
Fig. 3. It clearly showed the presence of Ca, P, Zn and O in
the zinc-doped hydroxyapatite structure. The decrease in
the Ca/P upon increase in the zinc concentration suggests
that Ca
2? in crystal lattice of hydroxyapatite reduces with
the increase of Zn
2?. The expected [Ca]/[P] wt ratio is
2.15, according to the stoichiometry of pure hydroxyapa-
tite. Table 4 indicates that the stoichiometry deviation of
the ([Ca] ? [Zn])/[P] wt ratios are higher than the [Ca]/
[P] ratios of the pure samples. In the doped samples, apart
from the incorporation of carbonate groups, other mecha-
nism can cause deviation from stoichiometry. In all the
samples the [Ca]/[P] wt ratios are higher than the expected
ones and they are around 2.4. It means that the samples are
about 14% P deﬁcient, but these values are within the [Ca]/
[P] limits that the hydroxyapatite structure can accommo-
date. They are also compatible with the values found in the
mineral part of human bones. EDX measurements indi-
cated that the average [Ca]/[P] ratios in the pure sample is
2.83, 30% higher than the expected values of 2.15. This
difference can be explained by incorporation of carbonate
groups substituting the phosphate ones in the hydroxyap-
atite matrix. This is an advantage of the chemical route
used in the present work since the carbonate groups are
known to accelerate the re-absorption of hydroxyapatite
implants. In the Zn
2?-doped samples, the EDX results
indicates the deviation from stoichiometry, with
([Ca] ? [Zn])/[P] ratios of about 2.24, 14% higher than the
2.15 expected value. This indicates that the dopant
enhances the incorporation of carbonate groups. Synthetic
hydroxyapatite is similar to the hydroxyapatite of human
bones and tooth and contains carbonate groups. The car-
bonate groups occupy phosphate sites leading to P deﬁ-
ciency. The pure hydroxyapatite samples were prepared in
air and thus there is a reasonable chance that carbonates are
formed via reaction of the hydroxyl groups in the aqueous
suspension with the CO2 present in the atmosphere forming
H2CO3 that is easily dissolved in water. The carbonate
groups are then free to be incorporated in the hydroxyap-
atite nanoparticles occupying the phosphate sites in the
hydroxyapatite structure. This substitution, however, did
not cause appreciable change in the XRD pattern of
hydroxyapatite since the X-Ray scattering factors for
phosphates and carbonates are not very different and the
amount of phosphate substitution by carbonates is quite
low: around 30% and 14% in Zn-doped hydroxyapatite
according to the EDX results, below the detection limit of
XRD in this particular case. On the other hand, the
Table 2 Single crystal size and crystallinity of Zn-doped
hydroxyapatite
Sample Line
width
(211)
FWHM
()
Line width
(211)
FWHM
(rad)
Average
single
crystal size
D( A ˚)
Crystallinity
(Xc)
Hydroxyapatite 0.156 0.002722 52 3.641
2% Zinc-doped
hydroxyapatite
0.161 0.00280945 50 3.312
3% Zinc-doped
hydroxyapatite
0.267 0.00465915 30 0.726
4% Zinc-doped
hydroxyapatite
0.292 0.0050954 27 0.555
5% Zinc-doped
hydroxyapatite
0.347 0.00605515 23 0.330
Table 3 Cell parameters of zinc-doped hydroxyapatite
Sample a (A ˚) c (A ˚) V (A ˚)
Hydroxyapatite 9.4360 ± 0.0818 6.8928 ± 0.1273 531.500
2% Zinc-doped
hydroxyapatite
9.4255 ± 0.0582 6.8860 ± 0.1069 530.562
3% Zinc-doped
hydroxyapatite
9.3791 ± 0.0949 6.8590 ± 0.0152 522.531
4% Zinc-doped
hydroxyapatite
9.3516 ± 0.0022 6.8303 ± 0.0022 522.030
5% Zinc-doped
hydroxyapatite
9.3365 ± 0.0163 6.8275 ± 0.1656 521.211
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123reabsorption of implants made with hydroxyapatite is faster
when carbonate groups are present in the hydroxyapatite
structure (Koort et al. 2008).
The zinc-doped hydroxyapatite samples were analyzed
by ICP-OES spectroscopy to ﬁnd out the amount of zinc
present in the zinc-doped hydroxyapatite samples. Table 5
Fig. 2 a Bright ﬁeld TEM image of pure hydroxyapatite. b TEM image of i 2 wt% zinc-doped hydroxyapatite, ii 3 wt% zinc-doped
hydroxyapatite, iii 4 wt% zinc-doped hydroxyapatite, iv 5 wt% zinc-doped hydroxyapatite
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123Fig. 3 EDX spectrum of zinc-doped hydroxyapatite. a 2% Zinc-doped hydroxyapatite, b 3% zinc-doped hydroxyapatite, c 4% zinc-doped
hydroxyapatite, d 5% zinc-doped hydroxyapatite
Table 4 Calculation of weight concentration ratios of hydroxyapatite
and zinc-doped hydroxyapatite via EDX
Sample Ca/P (wt%) (Ca ? Zn)/P (wt%)
Hydroxyapatite 2.79 2.79
2% Zinc-doped hydroxyapatite 2.60 2.62
3% Zinc-doped hydroxyapatite 2.56 2.50
4% Zinc-doped hydroxyapatite 2.27 2.31
5% Zinc-doped hydroxyapatite 2.20 2.24
Table 5 ICP-OES values of weight percentage of zinc in zinc-doped
hydroxyapatite
S. No Sample Zinc concentration
(Weight %)
1 2% Zinc-doped Hap 0.4990
2 3% Zinc-doped Hap 0.7400
3 4% Zinc-doped Hap 0.9710
4 5% Zinc-doped Hap 1.3740
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123gives the amount of zinc in the zinc-doped hydroxyapatite
samples. The amount of zinc increases with increase in the
amount of zinc added in the mother liquid.
The amount of zinc in the zinc-doped hydroxyapatite
was quantitatively conﬁrmed by XRF. The relative
amounts of Ca, Zn and P in the nanoparticles are listed in
Table 6. The XRF results agree with the ICP-OES results
regarding the zinc concentration. The zinc content of the
samples is lower than those of corresponding amount of
starting material. This implies that some of the Zinc ions
remain in the mother solution after precipitation. Pure
hydroxyapatite has a theoretical composition of Ca/P wt
ratio, 2.15. The Ca/P wt ratios of pure and all Zinc-doped
hydroxyapatite powders were higher than that of the
stoichiometric hydroxyapatite. The addition of Zinc seems
to affect the stoichiometry of hydroxyapatite. The stoi-
chiometry of Zinc-doped hydroxyapatite is compared with
the (Ca ? Zn): P ratio because Zinc is likely to replace
some Ca ions. The increase in the amount of Zinc
decreased the (Ca ? Zn): P ratio. This might be due to
the generation of crystal defects from Zinc substitution.
The (Ca ? Zn): P ratio for 2 and 3% zinc-doped
hydroxyapatite is 2.67 and 2.64, respectively. The Ca/P
ratio for pure hydroxyapatite is 2.83. The (Ca ? Zn): P
ratio for 2 and 3% zinc-doped hydroxyapatite shows a
slight variation from the Ca/P ratio of pure hydroxyapa-
tite. For 4 and 5% Zinc-doped hydroxyapatite the
(Ca ? Zn): P ratio is 2.35 and 2.29, respectively, where
the variation is larger. This shows that in 2 and 3% zinc-
doped hydroxyapatite most of the Zn
2? ions substitute the
position of Ca
2? in the apatite lattice. However, in 4 and
5% zinc-doped hydroxyapatite it seems that not all the
Zn
2? ions are in the substitutional position. This is con-
ﬁrmed from the XRD, FTIR and EDX analysis where
there is no existence of any noticeable diffraction peak
and band other than that of hydroxyapatite.
The structure of the ciproﬂoxacin-loaded hydroxyapa-
tite was analyzed using FTIR spectroscopy As Shown in
(Fig. 4). Characteristic structural bands of both hydroxy-
apatite and ciproﬂoxacin were observed for all hydroxy-
apatite/drug samples. The hydroxyapatite loaded with
drug represents mixed bands typical of hydroxyapatite
(P–O at 566, 602, 962, 1,091 and O–H at 632, 3,564) and
ciproﬂoxacin(C=C stretching at 1,608, CH2 bending at
1,468, mixed vibrations at 1,311, CH in plane bending at
1,272, CN stretching at 867). The corresponding band
intensities increase with increase in the drug loading
percentage. The drug-free hydroxyapatite shows little
difference conﬁrming that the drug has no signiﬁcant
effect on the structure.
The structure of ciproﬂoxacin and the optimized
geometry deduced through Gaussian 03 W is given in
(Fig. 5). The Raman spectrum of ciproﬂoxacin-loaded
hydroxyapatite is shown in (Fig. 6). The observed Raman
frequencies agree quite well with the literature. The most
prominent peaks at 1,379 and 1,622 are associated with the
ring vibrations. The Raman spectrum of hydroxyapatite
loaded with various concentration of drug is given in
(Fig. 6). It is interesting to note that the above peaks are
more pronounced and it is highest for 5% and least for 20%
drug loading. The frequencies of vibrations of PO4
3- ion
are also shifted to lower wave number region. The ring
stretching vibration at 1,622 cm
-1 for drug gets shifted to
lower wave number region on coating of the drug on
hydroxyapatite. It shifts to 1,605 cm
-1 for 5% drug con-
centration, 1,597 cm
-1 for 10% drug concentration and
1,591 cm
-1 for 20% drug concentration. The shift is more
for 20% while considering the structure of the drug there
are three possible sites for molecular adsorption on
hydroxyapatite: (1) the aromatic ring (2) the carbonyl
groups and (3) lone pair electrons of the hydrogen atoms.
According to the charge transfer idea of SERS, the
charge transfer between the adsorbed molecule and the
substrate is controlled by molecular frame vibration. It is
modulated by the vibration of those adsorbed groups that
are linked directly to the surface. A perpendicular orien-
tation of the drug molecule would result through carbonyl
groups. In the present case the carbonyl stretching mode is
not observed or may be very week. This eliminates the
possible adsorption through carbonyl groups. The obser-
vation of enhancement in the intensity of ring vibrations
suggests that there will be charge transfer between the drug
and the hydroxyapatite through p bonds. The observation
of shifts in the frequencies of PO4 vibrations suggests that
Table 6 Chemical composition of hydroxyapatite and zinc-doped hydroxyapatite by XRF
Sample Ca (wt%) Zn (wt%) P (wt%) Zn: (Ca ? Zn)
(wt%)
Ca: P
(wt%)
(Ca ? Zn):
P (wt%)
Ca: (P ? Zn)
(wt%)
Zn: (P ? Zn)
(wt%)
Hydroxyapatite 73.940 0 26.060 0 2.83 2.83 2.83 0
2% Zinc-doped hydroxyapatite 72.230 0.533 27.237 0.00732 2.65 2.67 2.60 0.019
3% Zinc-doped hydroxyapatite 71.919 0.611 27.470 0.00842 2.61 2.64 2.56 0.021
4% Zinc-doped hydroxyapatite 69.229 0.921 29.850 0.01312 2.31 2.35 2.24 0.029
5% Zinc-doped hydroxyapatite 68.370 1.300 30.330 0.01865 2.25 2.29 2.16 0.041
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123the drug molecules are very nearer to the PO4 groups.
Hence it can be concluded that the drug molecule has an
interaction with hydroxyapatite with a ﬂat on orientation
with their p electron clouds.
Drug loading
Drug loading efﬁciency of hydroxyapatite was examined as
described previously. It is dependent on the concentration
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Fig. 4 FTIR spectrum of ciproﬂoxacin-loaded hydroxyapatite
Fig. 5 a Structure of ciproﬂoxacin, b optimized geometry of
ciproﬂoxacin deduced through Gaussian 03 W
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123of drug and the ratio of drug and hydroxyapatite. The drug
loading percentage increases with increase in these
parameters. It increases and becomes constant at a partic-
ular level. The variation in drug loading with change in
drug concentration is given in (Table 7). For 5% drug
concentration the drug loading is 90% and it increases to
96% at 10% drug concentration and remains same for 20%
drug concentration. The variation in drug loading with
change in temperature is given in (Table 8). With 5% drug
concentration and 40-min stirring time, as the temperature
is increased the drug loading increases and attains a max-
imum of 90% at 60 C and then it becomes constant. With
5% drug concentration and temperature 60 C the variation
in drug loading with increase in stirring time is given in
(Table 9). Maximum drug loading is obtained in 40 min
and then it becomes constant. The optimized parameters,
40-min stirring time and 60 C, are used for drug loading.
Ciproﬂoxacin (5% concentration) was loaded on all the
four zinc-doped hydroxyapatite samples. The drug loading
with various zinc concentration is given in (Table 10).
There is no change in the drug loading percentage with the
incorporation of zinc.
In vitro drug release
Many carrier systems are used for the controlled delivery
of ciproﬂoxacin. Poly (DL)-lactide matrix are used for
infection therapy (Chouhan and Bajpai 2010). It showed a
controlled release in in vivo analysis. Ciproﬂoxacin-loaded
poly (2-hydroxyethyl methacrylate) shows a biphasic
release curve. It proved moderately effective in killing both
gram-positive and gram-negative bacteria (Norris et al.
2005). Ultrasonically controlled release of ciproﬂoxacin is
also achieved by pHEMA hydrogels (Chouhan and Bajpal
2009). Poly-(2-hydroxyethyl methacrylate) is used for the
delivery of 5-ﬂuro-uracil (Vijayakumar and Jain 2007).
Ciproﬂoxacin-loaded Human serum Albumin nanoparticles
give a controlled release of 20 h (Soriano de Souza et al.
2011). Since hydroxyapatite nanoparticles are naturally
present in bone, they are used for the delivery of antimi-
crobial like chlorhexidine and gentamicin for bone infec-
tions (Liu et al. 2010; Akashi et al. 2001).
Ciproﬂoxacin was loaded on hydroxyapatite to investi-
gate the efﬁcacy of the drug delivery system. The different
drug release proﬁles were well illustrated in (Fig. 7). The
estimated percentages of drug released in 600 h were found
to be 88, 75 and 61% from 20, 10 and 5% drug-loaded
samples, respectively. The drug is released gradually over a
Table 7 Drug loading percentage with various drug concentrations
S. No Drug concentration (%) Drug loading (%)
15 9 0
21 0 9 6
32 0 9 6
Table 8 Drug loading percentage with different temperature
S. No Temperature ( C) Drug loading (%)
14 0 8 5
25 0 8 7
36 0 9 0
47 0 9 0
Table 9 Drug loading percentage with different stirring time
S. No Time (min) Drug loading (%)
12 0 8 7
24 0 9 0
38 0 9 0
4 160 90
Table 10 Drug loading percentage with different zinc concentration
S. No Zinc concentration (%) Drug loading (%)
12 9 0
23 9 0
34 9 0
45 9 0
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123period of time. This shows that the drug is released in a
controlled manner. The amount of drug released in 24 h of
time is well above the minimum inhibition concentration of
CPX which is 0.25–2 lg/ml for pathogens like S. aureus
and P. aeruginosa which cause bone infections. Such a
release proﬁle observed could provide a rapid delivery of
drug to give antibacterial effects at the infected site and a
sustained release to aid long-term healing and avoid the
toxic and adverse systemic effects caused by high con-
centration of antibiotics. The slow release of ciproﬂoxacin
is due to the presence of trapped carboxylic group, which
reacts with Ca in the hydroxyapatite and zinc-doped
hydroxyapatite (Baker 1987). The plotted graphs revealed
that all the samples showed typical drug release pattern
with a lag time which was similar to the pattern for the
membrane diffusion process of the drug (Matsunaga et al.
2010). The release of ciproﬂoxacin from hydroxyapatite
nanoparticles exhibits a typical two-stage release mecha-
nism. The drug release is high during the initial time and
then it reduces and becomes constant. Ciproﬂoxacin release
during the initial burst stage is due to desorption of cip-
roﬂoxacin molecules that are located on the surface of the
particles. These particles do not strongly interact with the
hydroxyapatite nanoparticles. During the in vitro drug
release analysis the hydroxyapatite absorbs the surrounding
ﬂuid into the nanoparticles. This leads to the dissolution
and exclusion of the loaded ciproﬂoxacin. When the large
particles break into smaller particles more ciproﬂoxacin
gets exposed to the ﬂuid. When the loosely adsorbed cip-
roﬂoxacin had almost completely desorbed, the drug
release becomes slow. The slow release of ciproﬂoxacin
molecules is due to the incorporation of the drug
hydroxyapatite nanoparticles. This results from the disso-
lution of the hydroxyapatite nanoparticles.
Drug release proﬁle from the zinc-doped hydroxyapatite
is given in (Fig. 8). The percentage of drug released
increases with increase in the zinc concentration. The per-
centages of drugs released in 600 h were estimated to be 85,
88, 92 and 15.60% from 2, 3, 4, 5% zinc-doped samples
respectively. There is a sudden outburst of drug in the initial
few hours and then the drug is released in a controlled
manner.Thedrugreleasepercentageincreaseswithincrease
in the zinc percentage from 2 to 5%. The concentration of
zincincreasesinthedopedsamplewhichisgivenbytheICP
analysis. But there is a slightly higher increase in the drug
release from 4 and 5% zinc-doped hydroxyapatite. The
release of zinc from zinc-doped hydroxyapatite along with
ciproﬂoxacin release may be the reason for the increase in
drug release. The mechanism by which zinc release induces
higher drug release is not known.
The incorporation of zinc into hydroxyapatite and the
mechanism of zinc incorporation have been studied
extensively by various researchers (Tang et al. 2009; Sogo
et al. 2004). The release of zinc from zinc-doped
hydroxyapatite and the increase in osteoblastic cell growth
by zinc-doped hydroxyapatite are well documented (Ito
et al. 2002; Vojislav Stanic et al. 2010). This simultaneous
release of zinc and ciproﬂoxacin will promote both osteo-
blastic cell growth and antimicrobial activity.
Antibacterial activity
The antibacterial activity of ciproﬂoxacin-loaded hydrox-
yapatite and zinc-doped hydroxyapatite against different
0 100 200 300 400 500 600
0
20
40
60
80
100
D
r
u
g
 
r
e
l
e
a
s
e
(
%
)
Time (hours)
 2% Zinc doped Hap 
 3% Zinc doped Hap
 4% Zinc doped Hap
 5% Zinc doped Hap
Fig. 8 Drug release percentage from the zinc-doped hydroxyapatite
Table 11 Zone of inhibition of as-synthesized ciproﬂoxacin-loaded
hydroxyapatite and ciproﬂoxacin-loaded hydroxyapatite zinc-doped
hydroxyapatite
S. No Sample Zone of Inhibition (cm)
Staphylococcus
aureus
Pseudomonas
aeruginosa
1 Ciproﬂoxacin (control) 2.0 2.4
2 5% Ciproﬂoxacin-loaded
hydroxyapatite
1.7 2.15
3 10% Ciproﬂoxacin-loaded
hydroxyapatite
2.0 2.6
4 20% Ciproﬂoxacin-loaded
hydroxyapatite
3.0 4.1
5 2 wt% Zinc-doped
hydroxyapatite ? 5%
ciproﬂoxacin
1.8 2.0
6 3 wt% Zinc-doped
hydroxyapatite ? 5%
ciproﬂoxacin
1.8 2.0
7 4 wt% Zinc-doped
hydroxyapatite ? 5%
ciproﬂoxacin
1.9 2.1
8 5 wt% Zinc-doped
hydroxyapatite ? 5%
ciproﬂoxacin
1.9 2.1
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123micro-organism was monitored. Disk diffusion method was
used to determine the zone of inhibition. The results of
antibacterial activity of ciproﬂoxacin-loaded hydroxyapa-
tite and zinc-doped hydroxyapatite are given in (Table 11).
The zone of inhibition around the ciproﬂoxacin (control)
and ciproﬂoxacin-loaded hydroxyapatite, against Pseudo-
monas aeruginosa is given in Fig. 9a and against Staphy-
lococcus aureus in Fig. 9b, respectively. The zone of
inhibition around the ciproﬂoxacin-loaded zinc-doped
hydroxyapatite against Pseudomonas aeruginosa is given
in Fig. 10a and against Staphylococcus aureus in
Fig. 10b. The zone of inhibition increases with increase in
the ciproﬂoxacin concentration. This is relevant with the
apparent amount of drug release. When the amount of
drug release increases the zone of inhibition also increa-
ses. All the ciproﬂoxacin-loaded zinc-doped hydroxyapa-
tite nanoparticles have the greater antibacterial activity
than ciproﬂoxacin-loaded pure hydroxyapatite, and the
Fig. 9 a Antimicrobial activity of i Ciproﬂoxacin (control), ii 5%
ciproﬂoxacin-loaded hydroxyapatite, iii 10% ciproﬂoxacin-loaded
hydroxyapatite, iv 20% ciproﬂoxacin-loaded hydroxyapatite against
Pseudomonas aeruginosa. b Antimicrobial activity of i Ciproﬂoxacin
(control), ii 5% ciproﬂoxacin-loaded hydroxyapatite, iii 10%
ciproﬂoxacin-loaded hydroxyapatite, iv 20% ciproﬂoxacin-loaded
hydroxyapatite against Staphylococcus aureus
Fig. 10 a Antimicrobial activity of i ciproﬂoxacin-loaded 2 wt%
zinc-doped hydroxyapatite, ii ciproﬂoxacin-loaded 3 wt% zinc-doped
hydroxyapatite, iii ciproﬂoxacin-loaded 4 wt% zinc-doped hydroxy-
apatite, iv ciproﬂoxacin-loaded 5 wt% zinc-doped hydroxyapatite
against Pseudomonas aeruginosa. b Antimicrobial activity of
i ciproﬂoxacin-loaded 2 wt% zinc doped hydroxyapatite, ii cipro-
ﬂoxacin loaded 3 wt% zinc doped-hydroxyapatite, iii ciproﬂoxacin
loaded 4 wt% zinc doped hydroxyapatite, iv ciproﬂoxacin-loaded 5
wt% zinc-doped hydroxyapatite against Staphylococcus aureus
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123ciproﬂoxacin-loaded antibacterial activity of zinc-doped
hydroxyapatite gets higher with the increase of zinc con-
centration. Since the crystallinity of hydroxyapatite
decreases with increase in wt% of Zn
2?, the surface area of
the nano grains increases thereby forming bonds with the
microorganisms and causes cell death. The proposed
antibacterial mechanism of Zn
2? is that the ions in the
crystal surface form strong bonds with thiole, imidazole,
amino and carboxyl groups of microorganism membrane
proteins, causing structural changes. A microorganism
membrane with structural changes exhibits a signiﬁcant
increase in permeability, leaving the microorganism cells
incapable of properly regulating transport through the
plasma membrane and, ﬁnally, causing cell death (Vojislav
Stanic et al. 2010).
Conclusion
A drug delivery system with hydroxyapatite and zinc-
doped hydroxyapatite was developed for use in bone
infections. Both pure hydroxyapatite and zinc-doped
hydroxyapatite can be used as drug delivery system for the
controlled delivery of ciproﬂoxacin. Ciproﬂoxacin can be
loaded on hydroxyapatite to enhance wound healing as a
drug delivery system. Ciproﬂoxacin-loaded zinc-doped
hydroxyapatite can be used for drug delivery and induce
cell growth. The antimicrobial property increases with
increase in the drug concentration and the amount of zinc.
The drug loading depends on the concentration of drug,
temperature and stirring time. The drug loading percentage
increases with increase in drug concentration, temperature
and stirring time and then becomes constant. The drug
release from zinc-doped hydroxyapatite is higher than the
drug release from pure hydroxyapatite. The drug release
proﬁle from both pure and zinc-doped hydroxyapatite
shows a controlled release. The higher release of cipro-
ﬂoxacin from zinc-doped hydroxyapatite is due to the
release of zinc from zinc-doped hydroxyapatite. Both zinc
and ciproﬂoxacin will be released when drug is loaded on
zinc-doped hydroxyapatite. This will induce both cell
growth and antimicrobial activity.
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